Clinical Trial Update: S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial of isatuximab (S1702) in relapsed or refractory primary systemic amyloidosis. Results were posted on 2025-02-27…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Amyloidosis

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Amorphous, Eosinophilic, and Acellular Deposit, Constipation | Phase 2 | Status: COMPLETED | Results posted: 2025-02-27